HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY
Weekly Update
How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo, O., Sevilimedu, V., Montagna, G. et al.
Ann Surg Oncol 28, 287–294 (2021).
Petruolo, O., Sevilimedu, V., Montagna, G. et al. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? Ann Surg Oncol 28, 287–294 (2021).
Synopsis: In this article the authors evaluate breast-conserving surgery (BCS) conversion rates with neoadjuvant chemotherapy (NAC) in patients with tumors too large for conservation. Borderline-BCS candidacy, HER2+/triple negative receptor status, tumor size, cN+ status, and mammographic calcifications are factors to consider when selecting patients for downstaging with NAC.
Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial
Lurvink, R.J., Tajzai, R., Rovers, K.P. et al.
Ann Surg Oncol 28, 265–272 (2021). https://rdcu.be/ckzYV
Citation: Lurvink, R.J., Tajzai, R., Rovers, K.P. et al. Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. Ann Surg Oncol 28, 265–272 (2021).
Synopsis: Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy as a palliative treatment for unresectable isolated colorectal peritoneal metastases results in concentrations equal to those reached with systemic chemotherapy.
Listen to the ASO's new podcast, Speaking of SurgOnc®
Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.
Listen to the podcast here.
ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.
Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.
